This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rennebeck, G. Articles by Kyprianou, N. Search for Related Content PubMed PubMed Citation Articles by Rennebeck, G. Articles by Kyprianou, N. Related Collections Tumor Biology Tumor Biology: Invasion and Metastasis

Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis?

Departments of Surgery/Urology and Molecular and Cellular Biochemistry, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky

Requests for reprints: Natasha Kyprianou, Division of Urology, University of Kentucky College of Medicine, MS283, 800 Rose Street, Lexington, KY 40536. Phone: 859-323-9812; Fax: 859-323-1944; E-mail: nkypr2{at}uky.edu.

Overcoming the androgen independence of prostate tumors is considered the most critical therapeutic end point for improving survival in patients with metastatic prostate cancer. Normal epithelial and endothelial cells can undergo apoptosis when detached from the extracellular matrix (ECM), via the anoikis phenomenon. In contrast, tumor cells upon detachment from the ECM are capable of evading anoikis and metastasizing to different distant organs. Is the biological repertoire of the epithelial and endothelial cells sufficient to account for the events associated with the process of anoikis during prostate cancer metastasis? Although there is no clear answer to this question, what has become increasingly evident from the existing evidence is that molecules that induce anoikis in tumor epithelial and endothelial cells provide exciting new leads into effective therapeutic targeting as well as markers of prostate cancer progression and prediction of therapeutic resistance. This review analyzes recent findings on anoikis regulators and discusses the relevance of this unique apoptosis mode in the development of metastatic prostate cancer and identification of molecular signatures for treatment of advanced disease. (Cancer Res 2005; 65(24): 11230-5)

This article has been cited by other articles:

				D. Melisi, S. Ishiyama, G. M. Sclabas, J. B. Fleming, Q. Xia, G. Tortora, J. L. Abbruzzese, and P. J. Chiao LY2109761, a novel transforming growth factor {beta} receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol. Cancer Ther., April 1, 2008; 7(4): 829 - 840. [Abstract] [Full Text] [PDF]

				J. B. Garrison, Y.-J. Shaw, C.-S. Chen, and N. Kyprianou Novel Quinazoline-Based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity Cancer Res., December 1, 2007; 67(23): 11344 - 11352. [Abstract] [Full Text] [PDF]

				I. A. Mawji, C. D. Simpson, M. Gronda, M. A. Williams, R. Hurren, C. J. Henderson, A. Datti, J. L. Wrana, and A. D. Schimmer A Chemical Screen Identifies Anisomycin as an Anoikis Sensitizer That Functions by Decreasing FLIP Protein Synthesis Cancer Res., September 1, 2007; 67(17): 8307 - 8315. [Abstract] [Full Text] [PDF]

				C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889. [Full Text] [PDF]